🇯🇵·7h agoIndustry
Tecentriq Filed for Additional Indication as Maintenance Therapy Following Definitive Chemoradiotherapy in Locally Advanced Esophageal Cancer
Publisher
C
Chugai Pharmaceutical
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Chugai Pharmaceutical
- Region
- Japan
- Scope
- Industry
- Published
- June 12, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: Industry
Related coverage
More related coverage
AbbVie News·7h ago
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
Farmak (Ukraine)·7h ago
Farmak International Opens Representative Office in Mexico
Chugai Pharmaceutical News·7h ago
テセントリク、局所進行の食道がんにおける根治的化学放射線療法後の維持療法として適応拡大申請
Ipsen·8h ago